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Summary Endocrine therapy represents the basis
for the treatment of estrogen receptor-positive breast
cancer, but several tumors harbor intrinsic resistance
and acquired resistance to endocrine therapy is in-
evitable in metastatic disease. Combination strategies
of endocrine therapy with targeted agents are aimed
to overcome endocrine resistance. The selective
CDK4/6 inhibitor palbociclib has shown promising
results in metastatic luminal breast cancer when used
in combination with endocrine therapy both in the
first-line setting as in pretreated women. The drug
showed a manageable safety profile with uncompli-
cated neutropenia as the most frequent side effect.
Approval was already granted in the US and is also
awaited during 2016 for Europe.
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Introduction
Loss of normal cell cycle regulation is one of the hall-
marks of cancers [1] and alterations of the compo-
nents involved in cell cycle control occur frequently
in breast cancer [2]. Therefore, inhibition of cyclin de-
pendent kinases (CDKs) is an attractive approach in
tumor therapy. Unselective CDK inhibitors, however,
have only limited activity in several tumor entities [3].
In contrast, selective CDK4/6 inhibitors show a very
favorable toxicity profile in addition to a remarkable
efficacy when combined with endocrine therapy in
the treatment of metastatic luminal breast cancer [4,
5]. Here we review the mechanism of action, the ra-
tionale for the use in luminal breast cancer, and the
available clinical data for CDK4/6 inhibitors.
Mechanism of action
Retinoblastoma (RB) captures a key function in cell
cycle control [6]. Under normal conditions the un-
phosphorylated RB is bound to members of the tran-
scription factor family E2F, which in turn are linked to
a protein called dimerization partner (DB). Mitogenic
signals stimulate the expression of cyclin D, which
activates the cyclin-dependent kinases 4 (CDK4) and
6 (CDK6), resulting in the phosphorylation of RB.
Thereby RB disassociates from E2F allowing the tran-
scription of E2F-dependent genes. Other cyclin-
CDK complexes (CDK2/cyclin E or cyclin A, CDK1/
cyclin A or cyclin B) augment this phosphorylation
process. E2F induces the expression of cell cycle
genes, including cyclins and CDKs, and of genes
involved in replication and mitosis enabling progres-
sion from G1-phase to S-phase and to mitosis (M-
phase). At the transition from M- to G1-phase, RB
is dephosphorylated and thereby activated again by
phosphatases. Importantly, the cell cycle is negatively
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Fig. 1 Mechanismof action (adapted fromKnudsen&Knudsen. NatRevCancer 2008 [6])
Fig. 2 Manyknowndriversof breast cancer result in cyclinD
regulation (adapted fromWitkiewiczAK&KnudsenES.Breast
CancerRes2014 [8])
regulated by intrinsic CDK inhibitors. Two families
of such CDK inhibitors are known: (1) INK4 (p16Ink4a,
p15Ink4b, p18Ink4c, p19Ink4d) inhibiting the cyclin D de-
pendent kinases CDK2, -4, and -6 and (2) Cip/Kip
(p21cip1, p27kip1, p57kip2) inhibiting the cyclin E and A
dependent CDK2 (Fig. 1; [6–8]).
Why is CDK4/6 inhibition reasonable in luminal
breast cancer?
In breast cancer, many known drivers like estrogen
receptor (ER) or HER2 lead to cyclin D accumula-
tion. Furthermore, important signaling pathways like
PI3K (phosphoinositide 3-kinase), MAPK (mitogen-
activated protein kinases), STAT (signal transducer
and activator of transcription), Wnt, and NFkB (nu-
clear factor kappa-light-chain-enhancer of activated B
cells) converge to cyclin D and cause cell cycle pro-
gression (Fig. 2; [8, 9]).
In addition, the CDK/RB pathway is frequently dys-
regulated in breast cancer either by cyclin D amplifi-
cation or overexpression, loss of RB through deletion,
mutation or gene methylation or due to p16 deletion
or methylation [2, 7, 8]. The frequency of these dif-
ferent mechanisms of cell cycle deregulation strongly
differs by breast cancer subtype: while cyclin D over-
expression is frequent in luminal tumors (especially
in luminal B tumors—up to 40%) and rare in triple
negative breast cancer (TNBC), RB loss is mainly re-
stricted to nonluminal tumors [8]. Not surprisingly,
such alterations of cell cycle regulators are associated
with worse prognosis in ER-positive breast cancer [8]
and are known mechanism of endocrine resistance
[10]. Consequently, CDK4/6 inhibition seems a rea-
sonable target for breast cancer treatment. Preclinical
data show that the sensitivity to CDK4/6 inhibition is
restricted to luminal and HER2 amplified cell lines,
while nonluminal cell lines harbor intrinsic resistance
[11]. This fact can partly be explained by the higher
frequency of RB loss in nonluminal tumors [8]. Since
RB is the main target of CDK4/6, cancers that have
lost RB, proliferate independently of CDK4 and -6 and
consecutively do not respond to CDK4/6 inhibition
[12]. Furthermore, a synergistic effect of CDK4/6 in-
hibitors and endocrine therapy has been shown in
preclinical models [11].
Clinical data
Three CDK4/6 inhibitors are currently under clinical
development: abemaciclib, ribociclib, and palbociclib
(Table 1). All three compounds showed promising re-
sults in phase I trials and many phase II and phase III
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Table 1 CDK4/6 inhibitorsunder clinical development
Drug Company Phase
Abemaciclib (LY2835219) Lilly Oncology III ongoing (MONARCH trials)
Ribociclib (LEE011) Novartis III ongoing (MONALEESA
trials)
Palbociclib (PD0332991) Pfizer III ongoing (PALOMA trials)
II and III published
trials are ongoing. To date clinical data beyond phase I
are only available for palbociclib.
Efficacy
Single agent phase II trial. In a single-arm phase II
trial 32 patients with metastatic breast cancer positive
for RB protein were treated with palbociclib 125 mg
orally on days 1– 21 of a 28-day cycle. Most pa-
tient had ER-positive/HER2-negative disease (84%),
5% had ER-positive/HER2-positive breast cancer and
11% suffered from TNBC. The median number of
prior cytotoxic regimens was two. Objective tumor
response, the primary endpoint of the study, was
achieved in 2 patients (5%) with ER-positive breast
cancer. Five further patients with ER-positive disease
had stable disease for at least 6 months, resulting in
a clinical benefit rate (CBR) of 19%. Overall median
progression-free survival (PFS) was 3.7 months (95%
CI 1.9–5.1). In the ER-positive subgroup, PFS was
longer compared to the ER-negative subgroup (P =
0.03) and those who had previously progressed on
endocrine therapy for advanced disease (P = 0.02).
Several biomarker candidates like RB expression and
localization, Ki-67, p16 loss, and CCND1 (gene en-
coding cyclin D1) amplification were investigated, but
failed, however, to identify a sensitive tumor popula-
tion [13].
PALOMA-1 phase II trial. The open-label, random-
ized phase 2 study PALOMA-1 included 165 post-
menopausal women with advanced ER-positive/
HER2-negative breast cancer who had not received
any systemic treatment for their advanced disease.
Patients were enrolled in two separate cohorts: in
cohort 1 without biomarker selection and in cohort 2
with selection for tumors with CCND1 amplification,
loss of p16Ink4a, or both. All patients were randomly
assigned 1:1 to receive letrozole 2.5 mg daily or letro-
zole 2.5 mg daily plus palbociclib 125 mg, given orally
once daily on days 1–21 of a 28-day cycle. A third of
patients had received adjuvant endocrine treatment
(17% with aromatase inhibitors). After a median fol-
low-up of 29 months, median PFS was 10.2 months
for the letrozole group and 20.2 months for the pal-
bociclib plus letrozole group (HR 0.488, 95% CI 0.319
to 0.748; one-sided P = 0.0004; Fig. 3; [4]).
The superiority of the combination treatment was
consistent across all demographic subgroups and
baseline prognostic factors, apart from patients with
a disease-free survival (DFS) of 12 months or less from
the end of adjuvant treatment. Because this subgroup
consisted of 29 patients only, this has to be interpreted
with caution. The number of patients with disease
stabilization for at least 6 months was significantly
higher in the combination arm compared to letro-
zole alone, resulting in a CBR of 81% vs. 58% (P =
0.0009). In contrast, the overall response rate (ORR)
was not statistically different between the treatment
arms (43% vs. 33%, P = 0.13). Also this trial failed
to establish a biomarker for CDK4/6 inhibition. The
hazard ratio (HR) for PFS was even lower in cohort 1,
where patients were included irrespective of cyclin D
and p16 expression within the tumor, compared to
cohort 2 (HR 0.299, 95% CI 0.156 to 0.572 and HR
0.508, 95% CI 0.303 to 0.853, respectively) [4].
PALOMA-3 phase III trial. The placebo-controlled,
multicenter phase III trial PALOMA-3 included 521
patients with advanced ER-positive/HER2-negative
breast cancer that had relapsed or progressed during
prior endocrine therapy. Patients were randomly as-
signed in a 2:1 ratio to receive palbociclib and fulves-
trant or placebo and fulvestrant until disease progres-
sion. Interestingly this study included premenopausal
women as well, who additionally received goserelin
in both treatment arms. The median PFS was shorter
compared to the first-line trial PALOMA-1, but the
hazard ratio was in the same range (9.2 months in
the experimental arm vs. 3.8 months in the control
arm; HR 0.42; 95% CI 0.32 to 0.56; P < 0.001). Also
in PALOMA-3 all patient subgroups benefited from
the addition of the CDK4/6 inhibitor to endocrine
therapy. Interestingly, the smallest benefit was again
in patients with a short DFS (≤24 months) with a HR
of 0.84 (95% CI 0.41–1.75). The percentage of patients
achieving tumor response was low and not statisti-
cally significant different between the two treatment
arms (10% and 6%). The CBR was 34% in the palbo-
ciclib arm compared to 19% in the fulvestrant alone
arm (P < 0.001) [5].
Safety
All three clinical trials showed a very similar toxicity
profile of palbociclib [4, 5, 13]. The most common ad-
verse events were myelosuppression with neutrope-
nia, leukopenia, anemia, and thrombocytopenia as
well as fatigue and nausea. In the PALOMA-3 phase III
trial grade 3/4 neutropenia occurred in 62% of the pa-
tients receiving palbociclib in combination with ful-
vestrant. Interestingly, the incidence of febrile neu-
tropenia was very low with 0.6% in both treatment
arms. The overall frequency of infections was slightly
higher in the palbociclib-fulvestrant group compared
with the placebo-fulvestrant group (34% vs. 24%).
The infections, mainly affecting the upper respiratory
tract, were mostly grade 1 and 2 (Table 2; [5]). No
grade 3 or grade 4 non-hematologic adverse events
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Fig. 3 Progression-








Table 2 Most frequent toxicities in thePALOMA-3phase III trial (n=517) [5]
Palbociclib + Fulvestrant (n = 345) Placebo + Fulvestrant (n = 172)
All in % Grade 3 in % Grade 4 in% All in % Grade 3 in % Grade 4 in %
Neutropenia 79 53 9 4 – <1
Leukopenia 46 25 <1 4 – <1
Anemia 26 3 – 10 2 –
Thrombocytopenia 19 2 <1 – – –
Fatigue 38 2 – 27 1 –
Nausea 29 – – 26 <1 –
Headache 21 <1 – 17 – –
Upper respiratory infection 19 <1 – 16 – –
Diarrhea 19 – – 17 <1 –
Constipation 17 – – 14 – –
Alopecia 15 – – 6 – –
were reported in more than 2% of patients receiving
palbociclib, both in the PALOMA-1 and 3 trial [4, 5].
Why is CDK4/6 inhibition not more toxic?
The central role of CDK4 and CDK6 in cell cycle con-
trol would suggest an unfavorable toxicity profile of
CDK4/6 inhibitors. In particular, because CDK4 and
CDK6 were thought to be essential for initiation of the
cell cycle in response to mitogenic stimuli. A knock-
out mice model, however, showed that CDK4/6-null
mice embryos display normal organogenesis and
most cell types proliferate normally. Nevertheless,
the embryos die in late gestation due to severe ane-
mia [14]. This experiment shows that hematopoietic
cells are dependent on CDK4/6 for cell cycle entry,
while other cells dispose of alternative mechanisms
to initiate cell proliferation upon mitogenic stimula-
tion. Consistently, the main toxicity of palbociclib and
other CDK4/6 inhibitors is bone marrow suppression.
Despite in part high-grade leukopenia and neutrope-
nia, the incidence of febrile neutropenia seems not
to be increased [4, 5]. This observation can probably
be explained by the different mechanisms of myelo-
suppression of CDK4/6 inhibition and chemotherapy:
bone marrow suppression by CDK4/6 inhibition oc-
curs through cell cycle arrest without apoptosis which
is reversible upon palbociclib withdrawal, while treat-
ment with chemotherapeutic agents like paclitaxel or
doxorubicin results in DNA damage and apoptotic cell
death causing prolonged cell growth inhibition [15].
Furthermore, study protocols dictate a consequent
side effect management with treatment interruptions
and dose reductions in case of high grade cytopenia.
The frequency of dose reductions in the PALOMA-3
trial was about 30% [5]. An analogous careful man-
agement is required in the daily routine in order to
keep the time of grade 4 neutropenia short and to pre-
vent a higher rate of neutropenic fever as observed in
the clinical trials.
Future directions
Palbociclib is already approved by the US Food and
Drug Administration (FDA) as first-line therapy in
combination with letrozole in ER-positive metastatic
breast cancer. Approval by the European Medicines
Agency (EMA) is expected during 2016. After approval,
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Fig. 4 Possible treatment
scenariosafter approval of
palbociclib
several treatment scenarios are supposable (Fig. 4);
however, trials to investigate the best treatment se-
quence in ER-positive metastatic breast cancer are
warranted. Especially the question if endocrine
monotherapy is still an option after progression to
a CDK4/6 inhibitor combination remains open.
Preclinical data suggest that the main mechanism
of resistance to CDK4/6 inhibitors is the upregulation
of alternate cell cycle components like cyclin E1 and
CDK2 [16–18]. Also increased cyclin D1 levels have
been described after acquired resistance to CDK4/6
inhibitors [16, 18]. Furthermore, changes in cytoskele-
tal organization by Rho/Rac pathway activation were
observed [18]. Interestingly, also activation of the
PI3K-AKT-mTOR pathway seems to be a mechanism
of resistance to palbociclib, which can be targeted
with PI3K- and mTOR inhibitors, respectively [18].
Conversely, rephosphorylation of retinoblastoma was
described in PI3K inhibitor resistant cell lines, mak-
ing them sensitive to inhibition of CDK4/6 [19]. Thus,
preclinical evidence exists for CDK4/6 inhibition be-
fore PI3K-mTOR inhibition and vice versa. Addition-
ally, preclinical models show a synergistic effect of
CDK4/6- and mTOR- or PI3K inhibitors [19, 20]. If
this observation proves true on a patient level and
if the combination is safe has to be demonstrated
in the clinical phase I/II trials that were already
initiated (ClinicalTrials.gov identifier NCT01857193,
NCT01872260, NCT02088684, NCT02154776).
In parallel, two adjuvant trials with palbociclib in
combination with endocrine therapy are recruiting:
the PENELOPE-B trial including patients with ER-
positive tumors and significant residual disease af-
ter neoadjuvant chemotherapy (NCT01864746) and
the PALLAS trial including pre- and postmenopausal
women with ER-positive stage II or III tumors
(NCT02513394).
Conclusion
CDK4/6 inhibitors like palbociclib enlarge the treat-
ment armamentarium for ER-positive, HER2-negative
breast cancer. Because of the favorable toxicity profile
and the significant prolongation of PFS, the combina-
tion of a CDK4/6 inhibitor with endocrine therapy will
most probably be the first-line therapy of choice for
most patients with advanced luminal breast cancer.
The results of the corresponding phase III first-line
trials (PALOMA-2, MONALEESA-2, and MONARCH-
3) are awaited soon and approval for palbociclib by
the EMA is expected during 2016. The best endocrine
partner (aromatase inhibitor [AI] vs. fulvestrant) has
to be established and trials investigating treatment
options after acquired resistance to CDK4/6 inhibi-
tion are required.
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